1-6 of 6
Jessica J. Lin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

Melissa L. Johnson, Beni B. Wolf, Judy S. Wang, Alexander Philipovskiy, Geoffrey I. Shapiro, Bruno Bockorny, Wei Guo, Jinshan Shen, Kai Yu Jen, MaryBeth LeRose, Tamieka Lauz Hunter, Mahesh Padval, Oleg Schmidt-Kittler, Namrata Bhatia, Sarita Dubey, Julia Suchomel, Johanna C. Bendell, Shekeab Jauhari, Jennifer Eng-Wong, Jessica J. Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF8.
https://doi.org/10.1158/1535-7163.MCT-24-0466
Published: 31 December 2024
View article titled, First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract C149: Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2

Stephen V Liu, Marc Peeters, Myung-Ju Ahn, Jessica J Lin, Yuichiro Ohe, Chung Cheung Thomas Yau, Walter Bordogna, Stuart Osborne, Sven Schwemmers, Harald Zeuner, Koichi Goto
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C149.
https://doi.org/10.1158/1535-7163.TARG-23-C149
Published: 01 December 2023
View article titled, Abstract C149: Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <em>NTRK</em> or <em>ROS1</em> fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
Journal Articles

Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors

Jessica J Lin, Melissa Johnson, Enriqueta Felip, Sai-Hong Ignatius Ou, Benjamin Besse, Christina Baik, Julien Mazieres, Yasir Elamin, Joshua E. Reuss, Anna Minchom, Aurelie Swalduz, Nick Pavlakis, Geoffrey Liu, Shirish Gadgeel, D. Ross Camidge, Jennifer A Green, Junwu Shen, John Soglia, Yuting Sun, Viola W Zhu, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B154.
https://doi.org/10.1158/1535-7163.TARG-23-B154
Published: 01 December 2023
View article titled, Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
Journal Articles

Abstract PR003: Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial

Jessica J Lin, Byoung Chul Cho, D. Ross Camidge, Sang-We Kim, Benjamin Solomon, Rafal Dziadziuszko, Benjamin Besse, Koichi Goto, Adrianus Johannes de Langen, Jürgen Wolf, Ki Hyeong Lee, Sanjay Popat, Christoph Springfeld, Misako Nagasaka, Enriqueta Felip, Nong Yang, Shun Lu, Steven Kao, Vamsidhar Velcheti, Parneet Cheema, Shanna Stopatschinskaja, Minal Mehta, Denise Trone, Felipe Ades, Christophe Y. Calvet, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR003.
https://doi.org/10.1158/1535-7163.TARG-23-PR003
Published: 01 December 2023
View article titled, Abstract PR003: Repotrectinib in patients with <em>ROS1</em> fusion-positive (<em>ROS1</em>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
Journal Articles

Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with ROS1+ advanced non-small cell lung cancer and with NTRK+ advanced solid tumors (TRIDENT-1)

Jessica J. Lin, Byoung Chul Cho, Christoph Springfeld, D. Ross Camidge, Benjamin Solomon, Christina Baik, Vamsidhar Velcheti, Young-Chul Kim, Victor Moreno, Anthonie J. van der Wekken, Enriqueta Felip, Dipesh Uprety, Denise Trone, Shanna Stopatschinskaja, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P224.
https://doi.org/10.1158/1535-7163.TARG-21-P224
Published: 01 December 2021
View article titled, Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with <em>ROS1</em>+ advanced non-small cell lung cancer and with <em>NTRK</em>+ advanced solid tumors (TRIDENT-1)
Journal Articles

Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial

Benjamin Besse, Christina Baik, Christoph Springfeld, Alice Hervieu, Victor Moreno, Lyudmila Bazhenova, Jessica J. Lin, D. Ross Camidge, Benjamin Solomon, Vamsidhar Velcheti, Anthonie J. van der Wekken, Enriqueta Felip, Dipesh Uprety, Denise Trone, Shanna Stopatschinskaja, Byoung Chul Cho, Alexander Drilon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P02-01.
https://doi.org/10.1158/1535-7163.TARG-21-P02-01
Published: 01 December 2021
View article titled, Abstract P02-01: Repotrectinib in patients with <em>NTRK</em> fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial